BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19757314)

  • 1. Rituximab maintenance therapy in central nervous system lymphoma?
    Murawski N; Pfreundschuh M
    Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
    Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O
    Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Pitini V; Arrigo C; Righi M
    Cancer; 2004 Dec; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
    [No Abstract]   [Full Text] [Related]  

  • 4. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Wong ET
    Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455
    [No Abstract]   [Full Text] [Related]  

  • 5. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
    Cheah CY; Seymour JF
    Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET; Tishler R; Barron L; Wu JK
    Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
    Yamanaka R
    Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
    Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab.
    Liu CY; Teng HW; Lirng JF; Chiou TJ; Chen PM; Hsiao LT
    Leuk Lymphoma; 2008 Oct; 49(10):2018-21. PubMed ID: 18728965
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
    Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A
    Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
    Nayak L; Abrey LE; Drappatz J; Gilbert MR; Reardon DA; Wen PY; Prados M; Deangelis LM; Omuro A;
    Leuk Lymphoma; 2013 Jan; 54(1):58-61. PubMed ID: 22656234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
    Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
    Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
    [No Abstract]   [Full Text] [Related]  

  • 13. Intra-CSF rituximab for lymhomatous meningitis.
    Chamberlain MC; Glantz MJ
    J Clin Oncol; 2007 Oct; 25(28):4508-9; author reply 4509-11. PubMed ID: 17906219
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab for bone lymphoma.
    Savage DG; Staron R
    Ann Intern Med; 2001 Jun; 134(12):1156-7. PubMed ID: 11412072
    [No Abstract]   [Full Text] [Related]  

  • 15. What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?
    Crump M
    Leuk Lymphoma; 2006 Dec; 47(12):2437-9. PubMed ID: 17169786
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Zhang J; Chen B; Xu X
    Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
    Bobillo S; Abrisqueta P; Carpio C; Raheja P; Castellví J; Crespo M; Bosch F
    Haematologica; 2018 Feb; 103(2):e92-e93. PubMed ID: 29242296
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
    Ohguro N; Hashida N; Tano Y
    Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab for BCL-2-positive cancers.
    Boughton B
    Lancet Oncol; 2003 Feb; 4(2):69. PubMed ID: 12573343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.